Blujepa From GSK
Pharmacy Times
JULY 18, 2025
Contraindications include hypersensitivity, QTc prolongation, and severe hepatic or renal impairment, with common adverse effects being gastrointestinal symptoms and dizziness. SHOW MORE The FDA recently approved gepotidacin oral tablets for the treatment of uncomplicated urinary tract infections (UTIs). 1 REFERENCES 1. News release.
Let's personalize your content